Shares of IGC Pharma, Inc. (NYSEAMERICAN:IGC – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $0.41. IGC Pharma shares last traded at $0.39, with a volume of 331,377 shares trading hands.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on IGC shares. StockNews.com started coverage on IGC Pharma in a research note on Monday, May 6th. They issued a “sell” rating on the stock. Ascendiant Capital Markets upped their price objective on shares of IGC Pharma from $3.25 to $3.50 and gave the company a “buy” rating in a research report on Monday, July 29th. Finally, Alliance Global Partners began coverage on shares of IGC Pharma in a research report on Wednesday, July 17th. They issued a “buy” rating and a $3.50 price objective for the company.
View Our Latest Stock Analysis on IGC Pharma
IGC Pharma Stock Up 4.6 %
IGC Pharma (NYSEAMERICAN:IGC – Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The construction company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). IGC Pharma had a negative net margin of 966.54% and a negative return on equity of 119.06%. The firm had revenue of $0.27 million during the quarter.
About IGC Pharma
IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.
Read More
- Five stocks we like better than IGC Pharma
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- How to Invest in the FAANG Stocks
- MarketBeat Week in Review – 8/5 – 8/9
- Find and Profitably Trade Stocks at 52-Week Lows
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.